Sirtuin 6 activator UBCS039 ameliorates hepatic lipogenesis through liver X receptor deacetylation
Authors:
- 20 November 2025
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 168 (Pt 2) , 115878
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea (2022R1C1C1003563)
This publication has 43 references indexed in Scilit:
- SIRT1 and SIRT6: The role in aging-related diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2023
- Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitisArchives of Pharmacal Research, 2022
- SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021
- SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non‐Small cell lung cancer and inhibit tumor progressionIUBMB Life, 2021
- Protective and Detrimental Roles of p38α Mitogen‐Activated Protein Kinase in Different Stages of Nonalcoholic Fatty Liver DiseaseHepatology, 2020
- Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate CellsHepatology, 2020
- Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLDHepatology, 2019
- Mouse Models of Nonalcoholic SteatohepatitisHepatology, 2018
- Structural Basis of Sirtuin 6 Activation by Synthetic Small MoleculesAngewandte Chemie International Edition, 2016
- Role of adenosine monophosphate‐activated protein kinase–p70 ribosomal S6 kinase‐1 pathway in repression of liver X receptor‐alpha–dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones†Hepatology, 2009